FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088224060> ?p ?o ?g. }

• W2088224060 endingPage "101" @default.
• W2088224060 startingPage "95" @default.
• W2088224060 abstract "High-dose interleukin-2 (IL-2) is the only approved immunologic therapy for advanced melanoma, but response rates are low and significant toxicities limit treatment to otherwise healthy patients. g209-2M is a nanopeptide engineered to mimic an epitope of the gp100 melanocyte differentiation protein that is recognized in a human leukocyte antigen (HLA)-restricted manner by melanoma tumor-infiltrating lymphocytes in some patients. Previous reports indicated that administration of the g209-2M peptide could induce g209-reactive circulating T cells in patients with melanoma and that the combination of g209-2M and high-dose IL-2 might be a more active treatment than high-dose IL-2 alone. Low-dose IL-2 is not active but has significant biologic effects, and because of a different toxicity profile, it can be offered to most patients. The primary objective of this cooperative group phase 2 study was to determine the activity of the combination of g209-2M and low-dose IL-2 in advanced melanoma. Twenty-six HLA appropriate patients with advanced melanoma received subcutaneous g209-2M peptide once every 3 weeks and subcutaneous IL-2 (5 million IU/m2) daily for 5 days during the first and second weeks. Patients were monitored for tumor response, toxicity, and induction of g209-reactive circulating T cells. There were no objective responses. There were no toxic deaths and no grade 4 toxicities. More than half of the patients experienced some grade 2 toxicity and one quarter experienced grade 3 toxicity. There was no convincing evidence by enzyme-linked immunospot or tetramer analysis of induction of g209-reactive circulating T cells. The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2." @default.
• W2088224060 created "2016-06-24" @default.
• W2088224060 creator A5006339833 @default.
• W2088224060 creator A5010940382 @default.
• W2088224060 creator A5016316795 @default.
• W2088224060 creator A5019723408 @default.
• W2088224060 creator A5055228684 @default.
• W2088224060 creator A5060100321 @default.
• W2088224060 creator A5060897770 @default.
• W2088224060 creator A5073130519 @default.
• W2088224060 creator A5083883593 @default.
• W2088224060 creator A5084436319 @default.
• W2088224060 creator A5084967339 @default.
• W2088224060 creator A5085317448 @default.
• W2088224060 creator A5089516753 @default.
• W2088224060 date "2006-01-01" @default.
• W2088224060 modified "2023-10-16" @default.
• W2088224060 title "Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma" @default.
• W2088224060 cites W1983806918 @default.
• W2088224060 cites W2000786003 @default.
• W2088224060 cites W2030105919 @default.
• W2088224060 cites W2064718707 @default.
• W2088224060 cites W2086116992 @default.
• W2088224060 cites W2088890805 @default.
• W2088224060 cites W2122951893 @default.
• W2088224060 cites W2139863489 @default.
• W2088224060 cites W4212876258 @default.
• W2088224060 cites W4230409530 @default.
• W2088224060 cites W4293241248 @default.
• W2088224060 doi "https://doi.org/10.1097/01.cji.0000195295.74104.ad" @default.
• W2088224060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16365605" @default.
• W2088224060 hasPublicationYear "2006" @default.
• W2088224060 type Work @default.
• W2088224060 sameAs 2088224060 @default.
• W2088224060 citedByCount "21" @default.
• W2088224060 countsByYear W20882240602013 @default.
• W2088224060 countsByYear W20882240602017 @default.
• W2088224060 countsByYear W20882240602019 @default.
• W2088224060 crossrefType "journal-article" @default.
• W2088224060 hasAuthorship W2088224060A5006339833 @default.
• W2088224060 hasAuthorship W2088224060A5010940382 @default.
• W2088224060 hasAuthorship W2088224060A5016316795 @default.
• W2088224060 hasAuthorship W2088224060A5019723408 @default.
• W2088224060 hasAuthorship W2088224060A5055228684 @default.
• W2088224060 hasAuthorship W2088224060A5060100321 @default.
• W2088224060 hasAuthorship W2088224060A5060897770 @default.
• W2088224060 hasAuthorship W2088224060A5073130519 @default.
• W2088224060 hasAuthorship W2088224060A5083883593 @default.
• W2088224060 hasAuthorship W2088224060A5084436319 @default.
• W2088224060 hasAuthorship W2088224060A5084967339 @default.
• W2088224060 hasAuthorship W2088224060A5085317448 @default.
• W2088224060 hasAuthorship W2088224060A5089516753 @default.
• W2088224060 hasConcept C126322002 @default.
• W2088224060 hasConcept C143998085 @default.
• W2088224060 hasConcept C147483822 @default.
• W2088224060 hasConcept C195616568 @default.
• W2088224060 hasConcept C203014093 @default.
• W2088224060 hasConcept C2776789287 @default.
• W2088224060 hasConcept C2777658100 @default.
• W2088224060 hasConcept C2777701055 @default.
• W2088224060 hasConcept C2778690821 @default.
• W2088224060 hasConcept C29730261 @default.
• W2088224060 hasConcept C502942594 @default.
• W2088224060 hasConcept C71924100 @default.
• W2088224060 hasConcept C8891405 @default.
• W2088224060 hasConcept C98274493 @default.
• W2088224060 hasConceptScore W2088224060C126322002 @default.
• W2088224060 hasConceptScore W2088224060C143998085 @default.
• W2088224060 hasConceptScore W2088224060C147483822 @default.
• W2088224060 hasConceptScore W2088224060C195616568 @default.
• W2088224060 hasConceptScore W2088224060C203014093 @default.
• W2088224060 hasConceptScore W2088224060C2776789287 @default.
• W2088224060 hasConceptScore W2088224060C2777658100 @default.
• W2088224060 hasConceptScore W2088224060C2777701055 @default.
• W2088224060 hasConceptScore W2088224060C2778690821 @default.
• W2088224060 hasConceptScore W2088224060C29730261 @default.
• W2088224060 hasConceptScore W2088224060C502942594 @default.
• W2088224060 hasConceptScore W2088224060C71924100 @default.
• W2088224060 hasConceptScore W2088224060C8891405 @default.
• W2088224060 hasConceptScore W2088224060C98274493 @default.
• W2088224060 hasIssue "1" @default.
• W2088224060 hasLocation W20882240601 @default.
• W2088224060 hasLocation W20882240602 @default.
• W2088224060 hasOpenAccess W2088224060 @default.
• W2088224060 hasPrimaryLocation W20882240601 @default.
• W2088224060 hasRelatedWork W1132391452 @default.
• W2088224060 hasRelatedWork W1979044599 @default.
• W2088224060 hasRelatedWork W2009867644 @default.
• W2088224060 hasRelatedWork W2021824670 @default.
• W2088224060 hasRelatedWork W2032061740 @default.
• W2088224060 hasRelatedWork W2363997565 @default.
• W2088224060 hasRelatedWork W3036615648 @default.
• W2088224060 hasRelatedWork W4292999066 @default.
• W2088224060 hasRelatedWork W4321482651 @default.
• W2088224060 hasRelatedWork W1981120125 @default.
• W2088224060 hasVolume "29" @default.
• W2088224060 isParatext "false" @default.
• W2088224060 isRetracted "false" @default.

• next